The number of patients with dental implants is yearly increasing as are the complications due to peri-implant diseases. Considering the high prevalence rates (43% of all treated subjects) and the lack of a current gold-standard treatment, active prevention of peri-implant diseases is rapidly becoming a clinical challenge in current dental implantology.
As of 1 December 2022, the EU-funded research and innovation collaborative project NOMAD has set out to develop the next generation of dental implants that can prevent peri-implant diseases. Coordinated by Prof. Annabel Braem from KU Leuven, the 10 NOMAD partners from 7 European countries will apply multiple biomaterial innovations to promote tissue integration and prevent/control biofilm formation and avoid peri-implant diseases (peri-implant mucositis and peri-implantitis). Ultimately, the research efforts in the NOMAD project aim to increase implant longevity and thus reduce the socio-economic burden associated with peri-implant diseases.
“In the NOMAD project, we will investigate different approaches suited for Ti and ZrO2 dental implants, respectively, utilizing additive manufacturing (also referred to as 3D printing) for custom-made personalized parts as well as controlled release materials and nanotechnology for an overall biomimetic treatment modality,” says Prof. Annabel Braem, who is proud to be able to lead this enthusiastic international team of experts in (bio)material innovations, additive manufacturing, nanotechnology, cell therapy, microbiology, clinical periodontology, dental implant manufacturing, technology transfer and science communication.
With the ambition to bring better peri-implant health to patients and reduce dental healthcare costs in Europe and worldwide, the NOMAD consortium kicked-off the project on 7-8 December 2022 in Leuven with representatives of KU Leuven, Centre National de la Recherche Scientifique, Ecole Centrale de Lyon, Universität Siegen, Anthogyr, Croom Medical, Glantreo, Educell, University Medical Center Groningen, Universidad Complutense de Madrid, Health House and Atrineo.
Stay tuned to follow NOMAD’s progress.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.